MedinCell Says Partner Filed US FDA Application for Once-monthly Schizophrenia Treatment

MT Newswires · 2d ago
01:10 AM EST, 12/10/2025 (MT Newswires) -- MedinCell (MEDCL.PA) said its partner Teva Pharmaceutical submitted a new drug application to the US Food and Drug Administration for the long-acting olanzapine injectable to treat schizophrenia in adults. The application covers the once-monthly, subcutaneous formula of schizophrenia, according to a Tuesday release. It is supported by data from the late-stage Solaris study, in which the drug achieved efficacy and safety goals in the broad adult population.